Page 33 - Read Online

Yoo et al. Hepatoma Res 2020;6:9 I http://dx.doi.org/10.20517/2394-5079.2019.49 Page 5 of 9 Table 2. Studies about HCC recurrence after receiving DAAs in patients with hepatitis C virus infection

Author
ANRS [33]
Nishibatake
Reig et al. [13]
Conti et al. [14]
Singal et al. [37]
Nagata et al. [20]
recurrence.
Cabibbo et al. [34]
Kinoshita et al. [35]
cohort study
cohort study
cohort study
cohort study
cohort study
cohort study
cohort study
Collaborative study
Study design
Prospective observation
Prospective observational
Retrospective observational
Retrospective observational
Retrospective observational
Retrospective observational
Retrospective observational
(n = 793)
CirVir cohort
- IFN (n = 156)
CUPILT cohort
- DAAs (n = 13)
- IFN (n = 1145)
- DAAs (n = 189)
- DAAs (n = 752)
- DAAs (n = 231)
- DAAs (n = 147)
HEPATHER cohort
Chronic hepatitis C
with DAAs (n = 59)
- untreated (n = 66)
- Untreated (n = 78)
with DAAs (n = 103)
with DAAs (n = 143)
- Untreated (n = 562)
Patient number
RFA for HCV-related HCC
Liver transplanted patients
Prior history of treated HCC
Prior history of treated HCC
Prior history of treated HCC
Prior history of treated HCC
in HCV-associated cirrhosis
Prior history of treated HCC
in HCV-associated cirrhosis
Prior history of treated HCC
for HCC with DAA (n = 314)
risk was comparable between DAA group and untreated group.
9.1
5.7
5.6
10.4
20.2
58.6
from LT
IFN 81.6
IFN 86.4
DAAs 21.6
DAAs 21.6
70 months
period (months)
Median follow-up
NA
NA
NA
NA
97.50%
91.00%
96.50%
96.80%
96.00%
SVR rate
- IFN (61%)
- IFN (54.2%)
- DAAs (60%)
- DAAs (55.4%)
- Untreated (51.2%)
HCC recurrence rate
HCC recurrence rate
- DAAs DAAs (45.1%)
Outcomes
Tumor recurrence (27.6%)
HCC recurrence rate (2.2%)
HCC recurrence rate (52.5%)
HCC recurrence rate (20.3%)
- DAA 1.11/100 person-month
HCC recurrence rate at 2years
HCC recurrence rate (28.81%)
- DAA 0.73/100 person-month
HCC: hepatocellular carcinoma; DAAs: direct-acting antivirals; NA: not available; HCV : hepatitis C virus; LT: liver transplantation; IFN: interferon
- Untreated 1.73/100 person-month
- Untreated 0.66/100 person-month
HCC treatment
IFN-free therapies
interferon regimen
to reduce recurrence of HCC
Conclusion
during the first 3 months of the treated period
increased or decreased risk of HCC recurrence
rates and patterns between patients who received
DAA therapy was not significantly associated with
There was no evidence of an increased risk of HCC
of tumor recurrence coinciding with HCV clearance
the expected rate according to previous studies with
viral eradication were similar between IFN-based and
higher than that observed in DAA unexposed patients
The observed recurrence rate of 2.2% was lower than
HCC recurrence after viral eradication The risks of early HCC occurrence and recurrence after
The study showed an unexpected high rate and pattern
recurrence in treated compared with untreated patients
interferon-based and direct-acting antiviral therapy after
DAA-induced resolution of HCV infection does not seem
There is no significant difference in early HCC recurrence
The study did not find an increase in HCC recurrence rate
The risk of HCC early recurrence was comparable and not
and the incidences of HCC recurrence were 12%, 26.6%, and 29.1% at 6-, 12-, and 18-month follow-ups. Although risk of HCC recurrence remained high, the
of HCC recurrence was not different between the two groups. This suggested that there was no evidence that DAA treatment increases the risk of HCC
Cabibbo et al. [34] reported a prospective multicenter study in Italy. The study included 143 patients with complete response after curative treatment of HCC,